Mega Genomics Delivers Strong Revenue Growth but Faces Profit Drag from One-Off Costs

Mega Genomics Limited ( (HK:6667) ) has issued an update.

Mega Genomics reported robust top-line growth for the year ended 31 December 2025, with operating revenue rising 50.5% year on year to RMB247.2 million on the back of expanded product categories, an improved product matrix, and optimized product structure. Despite this strong revenue performance, net profit declined to RMB27.0 million, weighed by one-off expenses related to resumption of trading, donations tied to the Tai Po fire and other public welfare projects, and a provision for impairment of financial assets that contrasted with a reversal in the prior year.

Excluding the impact of impairment changes and these non-recurring items, adjusted net profit edged up to RMB42.0 million from RMB39.3 million, indicating underlying profitability remained solid in the core business. The company’s continued expansion of its nationwide coverage and online distribution channels reinforces its positioning in China’s genetic testing market, suggesting it is strengthening operational resilience and market reach even as reported earnings face short-term pressure from exceptional costs and asset quality adjustments.

More about Mega Genomics Limited

Mega Genomics Limited is a leading genetic testing platform company in China, specializing in consumer genetic testing, cancer screening services, and related ancillary products. Leveraging a nationwide sales and marketing network that covers healthcare institutions in more than 340 cities and partnerships with e-commerce and online healthcare platforms, the company has performed approximately 26 million genetic tests as of 31 December 2025, underpinning its scale and market presence.

Average Trading Volume: 8,733

Technical Sentiment Signal: Hold

Current Market Cap: HK$1.63B

For detailed information about 6667 stock, go to TipRanks’ Stock Analysis page.